On July 29, 2026, the clinical trial registry recorded a status update for a study involving degarelix. The trial, titled "Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer," has a listed status of completed.
The study is registered under identifier NCT01542021 and is classified with a phase designation of not applicable. Degarelix, an approved compound, was studied in this trial as a form of androgen deprivation therapy administered before prostatectomy.
The trial focused on patients with intermediate and high risk prostate cancer, according to the registered title. No efficacy results, safety findings, or outcome data were included in this status update. The registry entry confirms only that the trial's status has changed to completed as of the date listed.
Readers seeking details on trial design, eligibility criteria, or any posted results should consult the original registry listing directly. This brief reflects only the status change recorded in the trial registry and does not include interpretation of trial outcomes.
For more background on degarelix, including its approved uses and regulatory status, see the compound overview.